ArticleRheumatology international2026
Frequency and associated factors of hepatic hemangioma in systemic lupus erythematosus patients undergoing abdominal imaging: a retrospective cohort study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic hemangioma may be detected in patients with systemic lupus erythematosus (SLE). This study aimed to determine the frequency, radiological characteristics, and potential associated factors of hepatic hemangioma in SLE patients undergoing abdominal imaging. We retrospectively evaluated 221 of 402 SLE patients followed at a tertiary university hospital who underwent abdominal imaging for clinical indications. Demographic, clinical, laboratory, and radiological data were collected from medical records. Factors associated with hepatic hemangioma were analyzed. A total of 221 SLE patients who underwent abdominal imaging were included. All patients underwent abdominal ultrasound as the primary imaging modality. The mean age was 49.62 ± 13.75 years, 86.4% were female, mean age at SLE diagnosis was 36.29 ± 14.48 years, and mean disease duration was 12.81 ± 8.14 years. The most common indication for abdominal imaging was asymptomatic/routine screening/pre-renal biopsy evaluation (n = 117, 53%). Hepatic hemangioma was detected in 11.8% (n = 26) of the imaged SLE patients. Among these, 69.2% were identified after SLE diagnosis, 27% concurrently, and 3.8% before diagnosis. Most hemangiomas were solitary (65.4%), with a mean diameter of 2.57 ± 2.22 cm. Patients with hepatic hemangioma had significantly longer disease duration (15.85 ± 7.82 vs. 12.40 ± 8.12 years; p = 0.043) and follow-up duration (15.38 ± 7.98 vs. 11.61 ± 7.89 years; p = 0.030) compared to those without. At SLE diagnosis, pleuritis (19.2% vs. 5.6%; p = 0.035), autoimmune hemolytic anemia (AIHA) (38.5% vs. 18.6%; p = 0.037), and C3 hypocomplementemia (80.8% vs. 55.4%; p = 0.014) were significantly more common in the hemangioma group. Multivariate logistic regression analysis revealed that longer SLE disease duration (OR 1.06 per year; 95% CI 1.01-1.12; p = 0.020) and presence of AIHA at diagnosis (OR 3.42; 95% CI 1.32-8.88; p = 0.011) were independently associated with hepatic hemangioma. Hepatic hemangiomas may be incidentally detected in SLE patients undergoing abdominal imaging. They were significantly more frequent in patients with longer disease duration and in those with AIHA at SLE diagnosis. However, these findings should be interpreted cautiously due to the retrospective design and selected nature of the study population. Prospective longitudinal studies with unselected SLE cohorts and appropriate control groups are needed to better define the true frequency and their associated factors of hepatic hemangiomas in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.